Small molecule · Antagonist of prostaglandin E2 receptor EP4 subtype (PTGER4) · developed by Adlai Nortye Biopharma Co.
Palupiprant is an orally bioavailable antagonist of the prostaglandin E2 receptor type 4 (EP4). It targets and blocks immunosuppressive tumor-associated myeloid cells in the tumor microenvironment, which is intended to reduce their immunosuppressive activity and tumor cell proliferation. It is studied in rectal cancer and locally advanced solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04975958 | Phase 1 | Locally Advanced Solid Tumor | Completed | ANL |
| NCT03152370 | Phase 1 | Neoadjuvant Therapy in Rectal Cancer | Completed | ANL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Locally Advanced Solid TumorNeoadjuvant Therapy in Rectal Cancer
See ANL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ANL catalysts and pipeline →